Panagora Asset Management
ABVC icon

Panagora Asset Management’s ABVC BioPharma ABVC Stock Holding History

Panagora Asset Management’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$38.9K Hold
36,682
– – ﹤0.01% 1224
2026
Q2 		$58K Buy
+36,682
New +$45.7K ﹤0.01% 1156

Other funds holding ABVC

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Panagora Asset Management's ABVC Position: Q3 2026 in Review

Panagora Asset Management held its ABVC BioPharma (ABVC) position steady in Q3 2026 at 36,682 shares worth $38.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1224.

Panagora Asset Management first reported a position in ABVC in Q2 2026 and has held it in 2 quarters since. The position peaked at $58K in Q2 2026. 11 funds tracked by Wall St. Rank hold ABVC as of Q3 2026.

  • Panagora Asset Management held 36,682 shares of ABVC BioPharma worth $38.9K as of Q3 2026.
  • Panagora Asset Management left its ABVC BioPharma share count unchanged in Q3 2026.
  • ABVC BioPharma made up ﹤0.01% of Panagora Asset Management's portfolio in Q3 2026, its #1224 holding.
  • Panagora Asset Management first reported a position in ABVC BioPharma in Q2 2026 and has held it in 2 quarters since.
  • Panagora Asset Management's ABVC BioPharma position peaked at $58K in Q2 2026.
  • 11 funds tracked by Wall St. Rank held ABVC BioPharma as of Q3 2026.

Based on Panagora Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.